AGP Picks
View all

Avian flu treatment market seen reaching $20.6B by 2030

Nov. 4, 2026
Avian flu treatment market seen reaching $20.6B by 2030
By AI, Created 15:00 UTC, Nov 04, 2026, AGP -

The Business Research Company says the global avian flu treatment market is on track to grow from $15.04 billion in 2026 to $20.6 billion by 2030, driven by outbreaks, better diagnostics and stronger pandemic preparedness efforts. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The avian flu treatment market is expanding as governments, health systems and drug developers respond to recurring outbreaks and pandemic risk. - Growth in diagnostics, surveillance and vaccine development is increasing demand for antiviral drugs, monoclonal antibodies and other treatment tools. - The market outlook signals continued spending on zoonotic disease preparedness and public health response capacity.

What happened: - The Business Research Company released its Avian Flu Treatment Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the market will grow from $13.77 billion in 2025 to $15.04 billion in 2026. - The report projects the market will reach $20.6 billion by 2030, implying an 8.2% CAGR over the forecast period. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to post the fastest growth rate in the coming years.

The details: - The report links recent growth to frequent avian influenza outbreaks, strategic antiviral stockpiling, government containment efforts, hospital treatment development and rising public awareness of health risks. - Longer-term growth is expected to come from more funding for zoonotic disease research, next-generation vaccines, expanded global disease monitoring networks and faster therapeutic response systems. - The report also points to wider use of advanced antiviral medications, accelerated vaccine development methods, increased monoclonal antibody use and broader early detection and surveillance programs. - Avian flu treatment includes medical approaches used to manage symptoms caused by avian influenza infections in humans. - Avian influenza primarily infects birds, but strains such as H5N1 and H7N9 have crossed into humans and can cause severe illness or death. - The report says improved awareness and diagnosis are major demand drivers because they help identify infections early and support containment. - The World Health Organization reported in April 2024 that more than 8,000 people in the United States were actively monitored between February 2022 and March 2024 after exposure to animals potentially infected with HPAI A (H5N1). - The report says public-health protection, pandemic prevention and safeguarding poultry industries from economic damage are also pushing market demand. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report offers a free sample download at the avian flu treatment market report sample. - The full report is available at the avian flu treatment market report.

Between the lines: - The report frames avian flu treatment as a preparedness market as much as a clinical one, with demand tied to surveillance, stockpiling and response planning. - The regional outlook suggests mature markets still lead in size, while emerging healthcare systems are becoming the main growth engine. - The emphasis on vaccines, antibodies and early detection points to a broader shift from reactive care toward faster containment.

What's next: - The market is likely to track outbreaks, government preparedness budgets and vaccine pipeline progress. - Growth will depend on how quickly countries expand monitoring systems and convert research funding into deployable treatments. - Investors and health suppliers should expect continued focus on pandemic readiness and zoonotic disease response.

The bottom line: - Avian flu treatment is set for steady growth through 2030 as outbreaks, surveillance and preparedness spending keep the market expanding.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Market Forecast Analysis

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Market Forecast Analysis

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.